NCT02017535

An Adaptive Treatment Strategy for Adolescent Depression-Continuation

A Personalized Approach to Achieving a Sustained Response to Treatment for Adolescent Depression

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: University of Minnesota · Academic / Other
• Sex: All
• Age: 12 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

Aim 1: Assess the feasibility and acceptability of the personalized continuation treatment strategy. Aim 2: Estimate variances of primary and secondary outcomes with the continuation treatment. Aim 3: Conduct exploratory hypothesis-generating analyses to inform further development of the personalized continuation treatment strategy to be tested in a subsequent R01 proposal.

Detailed description

Male and female adolescents (ages 12-18) will be eligible for the study if they completed acute phase treatment and showed at least a partial response to treatment (CGI-I of minimally improved or better (CGI-I \< 3)). Adolescents will enter continuation treatment having either received 12 sessions of IPT-A, 16 sessions of IPT-A, or 12 sessions of IPT-A plus fluoxetine.This is a continuation of the study "An Adaptive Treatment Strategy for Adolescent Depression (PTAD)" NCT01802437

Conditions

• Adolescent Depression

Interventions

Type	Name	Description
DRUG	Fluoxetine	Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
BEHAVIORAL	Interpersonal Psychotherapy	Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.

Timeline

• Start date: 2012-06-01
• Primary completion: 2018-10-01
• Completion: 2018-10-01
• First posted: 2013-12-20
• Last updated: 2020-03-23
• Results posted: 2020-03-23

Locations

1 site across 1 country: United States